Are Psychedelics Safe? An In-Depth Examination of Psychedelic Safety and Neurotoxicity

With the rise in interest surrounding psychedelic substances and their potential therapeutic benefits, questions of safety and neurotoxicity are critical for responsible discussion and informed use. This article delves into the safety profile of psychedelics, drawing on landmark studies like those by David Nutt and LD (lethal dose) data on psilocybin to offer a thorough examination of the risks and benefits associated with these substances.

Understanding Psychedelic Safety: A Data-Driven Approach

One of the most comprehensive efforts to assess the relative safety of various drugs was led by Professor David Nutt and published in The Lancet in 2010. Nutt and his team evaluated drugs based on multiple dimensions, including physical harm, dependence, and social harm. By measuring these factors, they created a data-driven index that classified substances according to their relative risk.

Interestingly, psychedelics such as psilocybin (found in magic mushrooms) and LSD were placed at the lower end of the harm spectrum, indicating that they pose less risk than many commonly used substances, including alcohol and tobacco. Nutt’s findings underscored that psychedelic substances do not present the same level of physical risk or dependence potential as many legal and illegal drugs.

Below is a visual representation of the relative harm scores of various substances, adapted from David Nutt's study:

This chart demonstrates that substances like alcohol and heroin score highly across physical, dependence, and social harm metrics, whereas psychedelics such as LSD and psilocybin (magic mushrooms) exhibit a much lower harm profile across these categories.

How Are Psychedelics Assessed for Safety?

When discussing psychedelic safety, several key factors are often considered:

1. Physical Toxicity and Lethal Dose (LD): This examines the potential for overdose and fatality, typically using an LD50 measure, which indicates the dose required to be fatal for 50% of a test population. In drug safety studies, LD is a critical metric because it helps establish the relative toxicity of a substance. For instance, a substance with a high LD50 means it would take a very large dose to be fatal, indicating low toxicity. By contrast, a low LD50 signals higher toxicity, as even small amounts could cause death.
2. Neurotoxicity: This addresses the potential for psychedelics to cause damage to brain tissue or alter neurological functioning in a harmful way.
3. Dependence Potential: This evaluates the potential for addiction and abuse.
4. Behavioral and Psychological Risks: These include the potential for “bad trips,” lasting psychological issues, and triggering latent mental health conditions.

Physical Toxicity: How Safe Are Psychedelics Compared to Other Drugs?

One of the most notable findings from Nutt’s study is that psychedelics such as psilocybin and LSD have a low physical toxicity profile. For context, the LD50 for psilocybin in rats is approximately 280 milligrams per kilogram (mg/kg), which would equate to a massive dose for a human—far beyond what a typical user would ingest. Given that the average recreational dose of psilocybin ranges between 10 to 30 mg, achieving a lethal dose in humans would be extremely difficult.

Compared to substances like alcohol and opioids, which have relatively low thresholds for toxicity, psychedelics are significantly less dangerous in terms of overdose risk. Alcohol, for example, has an LD50 that is achievable within a typical binge drinking session, while opioids present fatal overdose risks even at therapeutic doses in some cases.

Neurotoxicity: Do Psychedelics Damage the Brain?

Neurotoxicity remains a key concern in assessing drug safety. Neurotoxic substances can kill brain cells, cause permanent cognitive damage, or alter the function of neurotransmitters in ways that may lead to long-term psychological harm. Studies to date have not found evidence that classic psychedelics, such as psilocybin, LSD, and mescaline, cause neurotoxicity. Research using imaging techniques, including fMRI and PET scans, has shown that while psychedelics induce changes in brain connectivity, these effects are temporary and do not appear to be harmful.

On the contrary, psychedelics are now being studied for their positive effects on the brain, including promoting neurogenesis (the growth of new neurons), enhancing neuroplasticity (the brain's ability to reorganize and form new connections), and even exhibiting anti-inflammatory properties in neural tissue. These qualities make psychedelics promising for therapeutic applications in conditions like depression, PTSD, and other disorders where brain inflammation, rigid neural pathways, or impaired neurogenesis might play a role. Such benefits are part of why psychedelics are being investigated not only for mental health treatments but also for their potential to promote overall brain health.

Dependence Potential: Can Psychedelics Be Addictive?

A notable characteristic of classic psychedelics is their lack of dependence potential. Unlike stimulants, opioids, and alcohol, psychedelics do not create physical dependence or trigger the same compulsive drug-seeking behaviors seen in addictive substances. Nutt’s data indicates that psychedelics score exceptionally low on dependence risk. This has been corroborated by studies in both humans and animals, where psychedelics show minimal reinforcing effects, meaning users are unlikely to develop cravings or physical withdrawal symptoms.

In fact, psychedelics like psilocybin, ibogaine, and LSD are actively being researched as potential treatments for addiction to substances such as alcohol, nicotine, and opioids. Clinical studies have shown promising results, with many individuals reporting reduced cravings, decreased withdrawal symptoms, and lower relapse rates. Psilocybin, for instance, has shown potential to help individuals quit smoking, while ibogaine, derived from a West African plant, has demonstrated effectiveness in interrupting opioid dependence. These findings suggest that certain psychedelics may not only lack addiction potential themselves but may also serve as powerful tools in combating addiction to other, more harmful substances.

Psychological Risks: “Bad Trips” and Psychological Safety

While psychedelics do not typically cause physical harm, they do present psychological risks, primarily in the form of “bad trips” or challenging psychological experiences. Such experiences can induce intense fear, paranoia, or distress, which, in some cases, could exacerbate or trigger latent mental health conditions like psychosis or bipolar disorder.

These risks are more common in uncontrolled or recreational settings, where users may take high doses without adequate support. However, in controlled therapeutic environments, adverse psychological effects are far less common and often managed through integration therapy and support. Still, individuals with a family history of psychosis or certain psychiatric conditions may be advised against using psychedelics due to these risks.

Final Considerations: Safe Use and Future Research

While psychedelics appear relatively safe compared to many other drugs, they are not entirely without risk. Safe and informed use involves several key considerations:

• Set and Setting: Ensuring a safe, controlled environment and a positive mindset reduces the likelihood of adverse psychological effects.
• Dosage: Adhering to safe dosages minimizes the risk of experiencing overwhelming or distressing psychological effects.
• Integration and Support: Engaging with integration practices and support can help individuals process and understand their experiences.

The growing body of research, including Nutt’s landmark study, underscores that psychedelics hold a promising safety profile when used responsibly and may offer a safer alternative to other substances when utilized in therapeutic settings. As research continues, especially with controlled clinical trials, our understanding of psychedelic safety will deepen, opening avenues for their broader application in mental health treatment.

In summary, psychedelics, particularly psilocybin, demonstrate low physical toxicity, no apparent neurotoxic effects, and minimal addiction potential. For those considering psychedelic use, especially in a therapeutic context, these findings highlight the relative safety of these substances when used responsibly, with ongoing research providing a foundation for safer, more effective treatments.
‍

© 2024 Steve Elfrink. All rights reserved.